Telemetry Investments, L.L.C. Mustang Bio, Inc. Transaction History

Telemetry Investments, L.L.C.

$63.3 Million
Q4 2022

A detailed history of Telemetry Investments, L.L.C. transactions in Mustang Bio, Inc. stock. As of the latest transaction made, Telemetry Investments, L.L.C. holds 392,700 shares of MBIO stock, worth $74,613. This represents 0.24% of its overall portfolio holdings.

Number of Shares

392,700

Previous 452,500 13.22%

Holding current value

$74,613

Previous $212,000 26.89%

% of portfolio

0.24%

Previous 0.27%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.32 - $8.27 $19,136 - $494,546	-59,800 Reduced 13.22%	392,700 $155,000
Q3 2022 Nov 17, 2022	BUY	$0.46 - $7.2 $8,050 - $126,000	17,500 Added 4.02%	452,500 $212,000
Q2 2022 Aug 15, 2022	BUY	$0.58 - $1.13 $79,750 - $155,374	137,500 Added 46.22%	435,000 $254,000
Q1 2022 May 16, 2022	BUY	$0.73 - $1.81 $93,075 - $230,775	127,500 Added 75.0%	297,500 $300,000
Q4 2021 Feb 14, 2022	BUY	$1.66 - $2.64 $74,700 - $118,800	45,000 Added 36.0%	170,000 $282,000
Q3 2021 Nov 15, 2021	BUY	$2.58 - $3.36 $322,500 - $420,000	125,000 New	125,000 $336,000
Q1 2021 May 17, 2021	SELL	$3.02 - $5.16 $449,980 - $768,840	-149,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.66 - $4.18 $200,010 - $314,302	-75,192 Reduced 33.54%	149,000 $564,000
Q3 2020 Nov 16, 2020	SELL	$3.01 - $3.88 $15,049 - $19,400	-5,000 Reduced 2.18%	224,192 $706,000
Q2 2020 Aug 14, 2020	BUY	$2.33 - $4.6 $401,931 - $793,513	172,503 Added 304.3%	229,192 $729,000
Q1 2020 May 15, 2020	BUY	$1.91 - $4.52 $108,275 - $256,234	56,689 New	56,689 $152,000

Others Institutions Holding MBIO

# of Institutions

Shares Held

415K

Call Options Held

Put Options Held

Urban Wealth Management, LLC

22K
Shares

$4,172
0.04% of portfolio

View Full List

About MUSTANG BIO, INC.

Ticker MBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,222,000
Market Cap $20M
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...

More about MBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Telemetry Investments, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Telemetry Investments, L.L.C. with notifications on news.

Account

Telemetry Investments, L.L.C. Mustang Bio, Inc. Transaction History